FDA advisory backs Merck & Co's Gardasil for prevention of anal cancer and AIN in both men and women

January 19, 2011 By Leave a Comment

Posted in ‘thepharmaletter.com’ 19 November 2010 The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for drug giant Merck & Co’s (NYSE: MRK) Gardasil ([Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) for the prevention of anal cancer and [...]

[Continue reading...]
Filed Under: FDA Tagged With: , , , , ,

Many Fail to Finish HPV Series as Recommended

January 17, 2011 By Leave a Comment

By:  Michael Smith, North American Correspondent, MedPage Today 13 December 2010 Many girls and young women may not be completing all three doses of the quadrivalent human papillomavirus vaccine in a timely fashion, researchers reported.   In a single-institution retrospective analysis, only 14% of girls and young women completed all three doses within seven months [...]

[Continue reading...]
Filed Under: HPV Tagged With: , ,

Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany

January 17, 2011 By Leave a Comment

By:  Professor Martina Doren Originally published February 2010 For approximately 2 years now, cervical cancer has been “converted” from an oncological disease to an infectious disease, which is said to be preventable by and large by two vaccines licensed in many countries. However, human papillomavirus(HPV) vaccines differ from existing others, as the former target a [...]

[Continue reading...]
Filed Under: Germany, HPV, Pharmaceutical Companies, Vaccines, World News Tagged With: , , , , , ,

FDA Reviewers Endorse Gardasil for Anal Cancer Prevention

January 17, 2011 By Leave a Comment

By:  Emily P. Walker 15 November 2010 WASHINGTON — Merck’s quadrivalent human papillomavirus recombinant vaccine, Gardasil, appears safe and effective at preventing anal cancer in males and females ages 9 to 26, FDA reviewers said. The vaccine was approved in 2006 to treat genital warts and cervical, vulvar, and vaginal cancer in females ages 9 [...]

[Continue reading...]
Filed Under: FDA, HPV, Merck & Co., United States, Vaccines Tagged With: , , , ,

HPV Vaccine Side Effects as Expected

January 17, 2011 By Leave a Comment

Posted in ‘Prescription Cancer Drugs’ 10 October 2010 Side effects of the quadrivalent human papillomavirus vaccine (Gardasil) have been pretty much what researchers expected, the CDC and FDA reported, although there were enough instances of of fainting and blood clots reported to worry critics. With more than 23 million doses of the vaccine distributed, most [...]

[Continue reading...]
Filed Under: HPV, Vaccines Tagged With: , , ,

HPV: Who immunizes? Who pays?

January 17, 2011 By Leave a Comment

By:  Lynn Shapiro 08 October 2010 The anticipated approval of Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Merck] for women 27 to 45 years of age has thrown the issue of vaccine reimbursement for pharmacists into the spotlight. A Merck spokeswoman told Drug Topics that the company expects to hear [...]

[Continue reading...]
Filed Under: HPV, Vaccines Tagged With: , ,

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24—45 years: a randomised, double-blind trial

January 15, 2011 By

The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009 doi:10.1016/S0140-6736(09)60691-7:  Munoz, et al   Background: Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and [...]

[Continue reading...]
Filed Under: Gardasil / Silgard Injuries, Gardasil/Silgard Efficacy, Gardasil/Silgard Reactions, Gardasil/Silgard Vaccine Tagged With: , , , , ,

Anaphylaxis following quadrivalent human papillomavirus vaccination.

January 15, 2011 By

By:  Julia M.L. Brotherton, MD HPH, et al Published at www.cmaj.ca on Sept. 1, 2008.   Background:  In 2007, Australia implemented the National human papillomavirus (HPV) Vaccination Program, which provides quadrivalent HPV vaccine free to all women aged 12–26 years. Following notification of 7 presumptive cases of anaphylaxis in the state of New South Wales, [...]

[Continue reading...]
Filed Under: Cervarix, Cervarix Reactions, Gardasil / Silgard Injuries, Gardasil/Silgard Reactions, Gardasil/Silgard Vaccine Tagged With: , , ,